Metagenomi Therapeutics (MGX) Change in Accured Expenses (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Change in Accured Expenses data on file, last reported at -$2.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$2.0 million, up 23.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 76.68% YoY), and the FY2025 annual result was -$1.6 million, down 83.87% from the prior year.
• Change in Accured Expenses advanced to -$2.0 million in Q1 2026 per MGX's latest filing, from -$3.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.0 million in Q3 2025 and troughed at -$3.2 million in Q4 2025.
• A 4-year average of -$225769.2 and a median of -$318000.0 in 2024 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 539.67% in 2025 and fell as far as 902.83% in 2025.
• A 4-year view of Change in Accured Expenses shows it stood at $902000.0 in 2023, then sank by 135.25% to -$318000.0 in 2024, then sank by 902.83% to -$3.2 million in 2025, then soared by 36.38% to -$2.0 million in 2026.
• Business Quant data shows MGX's Change in Accured Expenses at -$2.0 million in Q1 2026, -$3.2 million in Q4 2025, and $4.0 million in Q3 2025.